LeadIQ logo
Learn more at LeadIQ.com

Insights

Loading spinner
Gathering insights about Zymeworks Inc.

Similar companies to Zymeworks Inc.

Zymeworks Inc. Tech Stack

Zymeworks Inc. uses 8 technology products and services including NetSuite, Veeva Vault, Google Font API, and more. Explore Zymeworks Inc.'s tech stack below.

  • NetSuite
    E-commerce
  • Veeva Vault
    Enterprise Content Management
  • Google Font API
    Font Scripts
  • jQuery Migrate
    Javascript Libraries
  • scikit-learn
    Machine Learning
  • Splunk
    Miscellaneous
  • New Relic
    Real User Monitoring
  • Yoast SEO
    Search Engines

Media & News

Zymeworks Inc.'s Email Address Formats

Zymeworks Inc. uses at least 1 format(s):
Zymeworks Inc. Email FormatsExamplePercentage
First.Last@zymeworks.comJohn.Doe@zymeworks.com
89%
FLast@zymeworks.comJDoe@zymeworks.com
4%
First.Last@zymeworks.comJohn.Doe@zymeworks.com
4%
First.Last@zymeworks.comJohn.Doe@zymeworks.com
3%

Frequently Asked Questions

Where is Zymeworks Inc.'s headquarters located?

Minus sign iconPlus sign icon
Zymeworks Inc.'s main headquarters is located at 114 E 4th Avenue Suite 800 Vancouver, BC V5T1G4 CA. The company has employees across 5 continents, including North AmericaEuropeAsia.

What is Zymeworks Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact Zymeworks Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Zymeworks Inc.'s stock symbol?

Minus sign iconPlus sign icon
Zymeworks Inc. is a publicly traded company; the company's stock symbol is ZYME.

What is Zymeworks Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Zymeworks Inc.'s official website is zymeworks.com and has social profiles on LinkedIn.

How much revenue does Zymeworks Inc. generate?

Minus sign iconPlus sign icon
As of September 2024, Zymeworks Inc.'s annual revenue reached $75M.

What is Zymeworks Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Zymeworks Inc.'s SIC code is 8731 - Commercial Physical and Biological Research NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Zymeworks Inc. have currently?

Minus sign iconPlus sign icon
As of September 2024, Zymeworks Inc. has approximately 299 employees across 5 continents, including North AmericaEuropeAsia. Key team members include Chief Scientific Officer: P. M.Chief Medical Officer: D. H.Vice President Human Resources And Dei: L. O.. Explore Zymeworks Inc.'s employee directory with LeadIQ.

What industry does Zymeworks Inc. belong to?

Minus sign iconPlus sign icon
Zymeworks Inc. operates in the Biotechnology Research industry.

What technology does Zymeworks Inc. use?

Minus sign iconPlus sign icon
Zymeworks Inc.'s tech stack includes NetSuiteVeeva VaultGoogle Font APIjQuery Migratescikit-learnSplunkNew RelicYoast SEO.

What is Zymeworks Inc.'s email format?

Minus sign iconPlus sign icon
Zymeworks Inc.'s email format typically follows the pattern of . Find more Zymeworks Inc. email formats with LeadIQ.

How much funding has Zymeworks Inc. raised to date?

Minus sign iconPlus sign icon
As of September 2024, Zymeworks Inc. has raised $38M in funding. The last funding round occurred on Dec 26, 2023 for $38M.

When was Zymeworks Inc. founded?

Minus sign iconPlus sign icon
Zymeworks Inc. was founded in 2003.
Zymeworks Inc.

Zymeworks Inc.

Biotechnology ResearchBritish Columbia, Canada201-500 Employees

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China. Zymeworks is rapidly advancing a deep pipeline of product candidates based on its experience and capabilities in both antibody-drug conjugates and multispecific antibodies. In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies.  

Section iconCompany Overview

Headquarters
114 E 4th Avenue Suite 800 Vancouver, BC V5T1G4 CA
Phone number
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
ZYME
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2003
Employees
201-500

Section iconFunding & Financials

  • $38M

    Zymeworks Inc. has raised a total of $38M of funding over 15 rounds. Their latest funding round was raised on Dec 26, 2023 in the amount of $38M.

  • $50M$100M

    Zymeworks Inc.'s revenue is in the range of $50M$100M

Section iconFunding & Financials

  • $38M

    Zymeworks Inc. has raised a total of $38M of funding over 15 rounds. Their latest funding round was raised on Dec 26, 2023 in the amount of $38M.

  • $50M$100M

    Zymeworks Inc.'s revenue is in the range of $50M$100M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.